• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi , Oct 23

Ranbaxy Laboratories said on Monday that it has earned the exclusive rights to market Sanvar, the new chemical entity (NCE) drug of Swiss biopharmaceutical company Debiopharm Group, in India, Bangladesh and Nepal.

The injectible molecule is a synthetic analogue of a naturally occurring hormone and is used in the treatment of gastroenterological problems.

Sanvar can be stored at room temperature allowing immediate administration, which advantage it enjoys over competitors.

The drug is currently undergoing Phase III clinical trials in the US where it holds orphan drug status; Debiopharm is expected to file for approval in early 2007.

Mr Sanjeev Dani, Regional Director (India & Middle East), Ranbaxy, said: "We are glad to partner with Debiopharm in the gastroenterology area and shall work towards creating a productive relationship by complementing each others strengths."

More Stories on : Announcements | Channels and Franchises | Pharmaceuticals | Ranbaxy Laboratories Ltd

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
Ranbaxy to market Swiss gastro drug

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line